Investment
Features
FeesSafety
Academy
More
Pluang+

Canaan beats Q2 EPS estimates but misses revenue, holds large crypto treasury, and buys back shares.

Company Fundamentals
08 Sep 2026
Gordon Thompson
View Source
Neutral
Canaan beats Q2 EPS estimates but misses revenue, holds large crypto treasury, and buys back shares.

Canaan Inc. reported Q2 2026 results with an EPS loss of $0.01, better than the expected $0.10 loss, showing improved profitability. However, revenue was $4.63 million, below the $5.91 million forecast, indicating weaker sales in its crypto mining hardware business. The company holds a significant cryptocurrency treasury with 1,915 BTC and 3,952 ETH and repurchased $7.4 million worth of shares to return value to investors. This mix of results highlights ongoing challenges in sales but a strong position in crypto assets and shareholder returns.

More News

Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026.

Opus Genetics gets Buy rating ahead of key gene therapy data release on Sept 9, 2026.

Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...

Analyst Insights
Bullish
44 minutes ago
GE to acquire CPP for $11.75B, boosting aerospace casting capacity and earnings potential

GE to acquire CPP for $11.75B, boosting aerospace casting capacity and earnings potential

General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...

Analyst Insights
Bullish
47 minutes ago
UNFI beats Q4 EPS estimates but misses revenue, expects growth ahead.

UNFI beats Q4 EPS estimates but misses revenue, expects growth ahead.

United Natural Foods, Inc. (UNFI) reported a Q4 adjusted EPS of $0.69, surpassing analyst expectations of $0.61, signaling strong profitability. However, revenue slightly missed estimates at $7.64 billion, down 0.7% from the previous year. Despite th...

Company Fundamentals
Bullish
55 minutes ago
Ionis Pharmaceuticals gets $85 price target despite heart drug trial failure

Ionis Pharmaceuticals gets $85 price target despite heart drug trial failure

Ionis Pharmaceuticals faced a setback when its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events, causing an 8.6% stock drop. However, an analyst from Canaccord Genuity maintained a bullish $85 price target, im...

Analyst Insights
Bullish
1 hour ago
Casey's General Stores to report Q3 earnings with strong analyst expectations on Sept 8, 2026.

Casey's General Stores to report Q3 earnings with strong analyst expectations on Sept 8, 2026.

Casey's General Stores will release its Q3 2026 earnings on September 8 after market close, with analysts expecting an EPS of $6.78 and revenue of $5.56 billion. The company has a strong history of exceeding earnings estimates, with an average surpri...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App